Compare Incyte Corporation (INCY) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Uranium Energy Corp — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Uranium Energy Corp trades at $11.38 (market cap $5.67B). The key difference: Incyte Corporation is far larger — about 4.3× Uranium Energy Corp's market cap, and Incyte Corporation is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals.
| INCY | UEC | |
|---|---|---|
Market Cap | $24.54B | $5.67B |
Sector | Health | Energy |
52-Week High | $129.93 | $20.14 |
52-Week Low | $81.61 | $9.04 |
Enterprise Value | $20.04B | $5.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Uranium Energy Corp (UEC) trades at $11.45, up 0.62% today, with a bullish technical signal supported by moving averages. The company shows significant financial challenges with a net income margin of -513.24% and negative cash flow from operations, though it maintains strong analyst support with 87.5% buy ratings. Recent news highlights insider selling but also optimistic long-term nuclear energy prospects.
UEC presents high-risk, high-reward potential driven by nuclear energy tailwinds, but faces substantial execution risks amid persistent losses and premium valuation. The stock's outlook hinges on production ramp-up success and uranium price movements, with current financials indicating cautious near-term investor sentiment despite bullish analyst consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
